Foghorn Therapeutics Q2 EPS $(0.70) Beats $(0.73) Estimate, Sales $5.60M Miss $6.26M Estimate
Portfolio Pulse from Benzinga Newsdesk
Foghorn Therapeutics (NASDAQ:FHTX) reported Q2 earnings per share (EPS) of $(0.70), beating the analyst consensus estimate of $(0.73) by 4.11%. However, the company's quarterly sales of $5.60 million missed the analyst consensus estimate of $6.26 million by 10.56%. This represents a 6.06% decrease in EPS and a 24.70% increase in sales compared to the same period last year.
August 04, 2023 | 3:06 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Foghorn Therapeutics' Q2 EPS beat estimates but sales missed. This mixed result could lead to uncertainty in the market.
Foghorn Therapeutics reported a better than expected EPS, which is a positive signal for investors. However, the company missed sales estimates, which could be a concern. The mixed results could lead to uncertainty in the market, potentially impacting the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100